Platelets in atherosclerosis

Thrombosis and Haemostasis

Volumn 106, Issue 5, 2011, Pages 827-838

  Lievens, Dirk ^a   von Hundelshausen, Philipp ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Inflammation; Platelet immunology

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CD40 LIGAND; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR4; EPTIFIBATIDE; FLUOXETINE; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; JUNCTIONAL ADHESION MOLECULE A; PADGEM PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE ACTIVATED RECEPTOR; PURINERGIC P2Y12 RECEPTOR; RANTES; SARPOGRELATE; SCAVENGER RECEPTOR; SEROTONIN; STROMAL CELL DERIVED FACTOR 1; TIROFIBAN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL INTERACTION; DENDRITIC CELL; ENDOTHELIUM CELL; GASTROINTESTINAL SYMPTOM; HOST RESISTANCE; HUMAN; INFLAMMATORY CELL; LEUKOCYTE; LEUKOCYTE ACTIVATION; LIBIDO DISORDER; MONOCYTE; NEUTROPHIL; PATTERN RECOGNITION; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; ATHEROSCLEROSIS; BLOOD PLATELETS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 80155193100     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0592     Document Type: Article

References (155)

1. Bizzozero J. Ueber einen neuen Formbstandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Archiv Pathol Anat 1865; 90: 261-332.
2. Smyth SS, et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7: 1759-1766.
3. Semple JW, et al. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
4. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci 2010; 67: 525-544.
5. Yeaman MR, et al. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob Agents Chemother 1992; 36: 1665-1670.
6. Nurden AT. Platelets, inflame ation and tissue regeneration. Thromb Haemost2011; 105 (Suppl 1): S13-33.
7. Li Z, et al. Platelets as immune mediators: Their role in host defense response andsepsis. Thromb Res 2011; 127: 184-188.
8. Gawaz M, et al. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
9. Senzel L, et al. The platelet proteome. Curr Opin Hematol 2009; 16: 329-333.
10. Koenen RR, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
11. von Hundelshausen P, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
12. van Gils JM, et al. Molecular and fun tional interactions among monocytes, platelets,and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol 2009; 85: 195-204.
13. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
14. Sarma J, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171.
15. Drechsler M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122: 1837-1845.
16. Kornerup KN, et al. Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. J Appl Physiol 2010; 109: 758-767.
17. Gawaz M, et al. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2008; 6: 235-242.
18. Duffau P, Seneschal J, Nicco C, et al. Platelet CD154 potentiates interferon-alpha ecretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010; 2: 47ra63.
19. Gerdes N, et al. Platelets regulate CD4+ T-cell differentiation via multiple chemokines in humans. Thromb Haemost 2011; 106: 353-362.
20. Siegel-Axel D, et al. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res 2008; 78: 8-17.
21. Ferroni P, et al. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol Haemost Thromb 2006; 35: 346-354.
22. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002; 106: 399-402.
23. Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res 2007; 100: 1673-1685.
24. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 728-739.
25. Bergmeier W, et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006; 103: 16900-16905.
26. Munnix IC, et al. The glycoprotein VI-phospholipase Cgamma2 signaling pathway ontrols thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vasc Biol 2005; 25: 2673-2678.
27. Varga-Szabo D, et al. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-412.
28. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359: 938-949.
29. Massberg S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197: 41-49.
30. Bennett JS. Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest 2005; 115: 3363-3369.
31. Angelillo-Scherrer A, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7: 215-221.
32. Andre P, et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 8: 247-252.
33. Ho-Tin-Noe B, et al. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008; 68: 6851-6858.
34. Massberg S, et al. A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion Formation. J Exp Med 2002; 196: 887-896.
35. Wang Y, et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 2005; 112: 2993-3000.
36. Kasirer-Friede A, et al. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood 2004; 103: 3403-3411.
37. Goto S, et al. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006; 47: 155-162.
38. Stolla M, et al. The kinetics of alphaIIbbeta3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood 2011; 117: 1005-1013.
39. Nesbitt WS, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15: 665-673.
40. Shpilberg O, et al. Patients with Glanzmann thrombasthenia lacking platelet glycoprotein alpha(IIb)beta(3) (GPIIb/IIIa) and alpha(v)beta(3) receptors are not protected from atherosclerosis. Circulation 2002; 105: 1044-1048.
41. Kucharska-Newton AM, et al. Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2011; 216: 151-156.
42. Massberg S, et al. Platelet adhesion via glycoprotein IIb integrin is critical for atheroprogression and focal cerebral ischemia: an in vivo study in mice lacking glycoprotein IIb. Circulation 2005; 112: 1180-1188.
43. Bigalke B, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27: 2165-2169.
44. Bultmann A, et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis-- a possible role of fibronectin. J Mol Cell Cardiol 2010; 49: 532-542.
45. Schulz C, et al. EMMPRIN (CD147/Basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost 2011; 9: 1007-1019.
46. Seizer P, et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost 2009; 101: 682-686.
47. Dole VS, et al. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 2005; 106: 2334-2339.
48. Dong ZM, et al. Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000; 101: 2290-2295.
49. Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 61.
50. Ridker PM, et al. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
51. Kisucka J, et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009; 113: 6015-6022.
52. Engel D, et al. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin Immunol 2009; 21: 308-312.
53. Lievens D, et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
54. Lutgens E, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5: 1313-1316.
55. Lutgens E, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
56. Henn V, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591.
57. Henn V, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
58. Chen C, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112: 3205-3216.
59. Lievens D, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
60. Zhou X, et al. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102: 2919-2922.
61. Ait-Oufella H, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180.
62. Danese S, et al. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol 2004; 172: 2011-2015.
63. Inwald DP, et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-1048.
64. Aslam R, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide- induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood 2006; 107: 637-641.
65. Hodgkinson C, Ye S. Toll-like receptors, their ligands, and atherosclerosis. Sci World J 2011; 11: 437-453.
66. Edfeldt K, et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-1161.
67. Kiechl S, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
68. Michelsen KS, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-10684.
69. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Tolllike receptor 2. J Clin Invest 2005; 115: 3149-3156.
70. Andonegui G, Kerfoot SM, McNagny K, et al. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417-2423.
71. Zhang G, et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009; 182: 7997-8004.
72. Yeaman MR, et al. Partial characterization and staphylocidal activity of thrombininduced platelet microbicidal protein. Infect Immun 1992; 60: 1202-1209.
73. Kramp BK, et al. Heterophilic chemokine receptor interactions in chemokine signaling and biology. Exp Cell Res 2011; 317: 655-663.
74. Riviere C, et al. Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood 1999; 93: 1511-1523.
75. Clemetson KJ, et al. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-4054.
76. Fujisawa T, et al. Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. J Allergy Clin Immunol 2002; 110: 139-146.
77. Schafer A, et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-412.
78. Combadiere C, et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003; 107: 1009-1016.
79. Lesnik P, et al. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
80. Meyer Dos Santos S, et al. The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib. Blood 2011; 117: 4999-5008.
81. Liu H, et al. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010; 24: 17-24.
82. Nergiz-Unal R, et al. CD36 as a multiple-ligand signaling receptor in atherothrombosis. Cardiovasc Hematol Agents Med Chem 2011; 9: 42-55.
83. Febbraio M, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049-1056.
84. Assinger A, Koller F, Schmid W, et al. Hypochlorite-oxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L--a prominent role of CD36. Atherosclerosis 2010; 213: 129-134.
85. Siess W, et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 1999; 96: 6931-6936.
86. van Willigen G, et al. LDLs increase the exposure of fibrinogen binding sites on platelets and secretion of dense granules. Arterioscler Thromb 1994; 14: 41-46.
87. Korporaal SJ, et al. Binding of low density lipoprotein to platelet apolipoprotein E receptor 2' results in phosphorylation of p38MAPK. J Biol Chem 2004; 279: 52526-52534.
88. Yaari S, Goldbourt, Even-Zohar S, et al. Associations of serum high density lipoprotein and total cholesterol with total, cardiovascular, and cancer mortality in a 7-year prospective study of 10 000 men. Lancet 1981; 1: 1011-1015.
89. Tenenbaum A, et al. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 2008; 45: 127-153.
90. Korporaal SJ, et al. Deletion of the high-density lipoprotein receptor scavenger receptor BI in mice modulates thrombosis susceptibility and indirectly affects platelet function by elevation of plasma free cholesterol. Arterioscl Thromb Vasc Biol 2011; 31: 34-42.
91. Ma Y, et al. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 2010; 116: 1932-1941.
92. Vergeer M, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364: 136-145.
93. Borissoff JI, et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 821-830.
94. Angiolillo DJ, et al. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010; 31: 17-28.
95. Kahn ML, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690-694.
96. Ebnet K, et al. Junctional adhesion molecules (JAMs): more molecules with dual functions? J Cell Sci 2004; 117: 19-29.
97. Orlova VV, Chavakis T. Regulation of vascular endothelial permeability by junctional adhesion molecules (JAM). Thromb Haemost 2007; 98: 327-332.
98. Malergue F, et al. A novel immunoglobulin superfamily junctional molecule expressed by antigen presenting cells, endothelial cells and platelets. Mol Immunol 1998; 35: 1111-1119.
99. Santoso S, et al. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 2002; 196: 679-691.
100. Zernecke A, et al. Importance of junctional adhesion molecule-A for neointimal lesion formation and infiltration in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol 2006; 26: e10-3.
101. Schall TJ, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol 1988; 141: 1018-1025.
102. Schall TJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669-671.
103. Schober A, et al. Deposition of Platelet RANTES Triggering Monocyte Recruitment Requires P-Selectin and Is Involved in Neointima Formation After Arterial Injury. Circulation 2002; 106: 1523-1529.
104. Veillard NR, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-261.
105. Brandt E, et al. Platelet-derived CXC chemokines: old players in new games. Immunol Rev 2000; 177: 204-216.
106. Kasper B, et al. Platelet factor 4 (PF-4)-induced neutrophil adhesion is controlled by src-kinases, whereas PF-4-mediated exocytosis requires the additional activation of p38 MAP kinase and phosphatidylinositol 3-kinase. Blood 2004; 103: 1602-1610.
107. Petersen F, et al. TNF-alpha renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J Immunol 1996; 156: 1954-1962.
108. Pitsilos S, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 90: 1112-1120.
109. von Hundelshausen P, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005; 105: 924-930.
110. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 2010; 9: 141-153.
111. Karshovska E, et al. Expression of HIF-1alpha in injured arteries controls SDF- 1alpha mediated neointima formation in apolipoprotein E deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 2540-2547.
112. Kathiresan S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
113. Mehta NN, et al. The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. Eur Heart J 2011; 32: 963-971.
114. Kiechl S, et al. Coronary artery disease-related genetic variant on chromosome 10q11 is associated with carotid intima-media thickness and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 2678-2683.
115. Merhi-Soussi F, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res 2005; 66: 583-593.
116. Brody JI, et al. Interleukin-1 alpha as a factor in occlusive vascular disease. Am J Clin Pathol 1992; 97: 8-13.
117. Kaplanski G, et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 1994; 84: 4242-4248.
118. Gawaz M, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75.
119. Boring L, et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
120. Lutgens E, et al. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 2005; 111: 3443-3452.
121. Gawaz M, et al. Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb Haemost 2002; 88: 307-314.
122. Assoian RK, et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983; 258: 7155-7160.
123. Bao W, et al. Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 2010; 116: 4639-4645.
124. Lutgens E, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-982.
125. Toma I, McCaffrey TA. Transforming growth factor-beta and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res 2011; epub ahead of print.
126. Heeschen C, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
127. Yacoub D, et al. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2424-2433.
128. Massberg S, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94: 3829-3838.
129. Anderson GM, Cook EH. Pharmacogenetics. Promise and potential in child and adolescent psychiatry. Child Adolesc Psychiatr Clin N Am 2000; 9: 23-42, viii.
130. Walther DJ, et al. Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release. Cell 2003; 115: 851-862.
131. Li N, et al. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8: 517-523.
132. Duerschmied D, et al. Serotonin stimulates platelet receptor shedding by tumor necrosis factor-alpha-converting enzyme (ADAM17). J Thromb Haemost 2009; 7: 1163-1171.
133. Satomura K, et al. Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease. Clinical Cardiol 2002; 25: 28-32.
134. Bampalis VG, et al. Fluoxetine inhibition of 5-HT-potentiated platelet aggregation in whole blood. Thromb Haemost 2010; 104: 1272-1274.
135. Andrade C, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-1575.
136. Dees C, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208: 961-972.
137. Soga F, et al. Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 2007; 127: 1947-1955.
138. Leon-Ponte M, et al. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 2007; 109: 3139-3146.
139. Muller T, et al. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009; 4: e6453.
140. Coccheri S. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs 2010; 70: 887-908.
141. Steinhubl SR, et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113-122.
142. Cyrus T, et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1282-1287.
143. Tous M, et al. Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Basic Clin Pharmacol Toxicol 2004; 95: 15-19.
144. Paul-Clark MJ, et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004; 200: 69-78.
145. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265: 956-959.
146. de Winther MP, et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 25: 904-914.
147. Afek A, et al. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res 2009; 77: 364-369.
148. Cha JK, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis 2002; 14: 145-150.
149. Hermann A, et al. Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
150. Evangelista V, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet dependent leukocyte activation. Thromb Haemost 2005; 94: 568-577.
151. Waehre T, et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 2006; 4: 2140-2147.
152. Naik UP, et al. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem 1997; 272: 4651-4654.
153. Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation 2005; 112: 2725-2734.
154. Buensuceso C, et al. Detection of integrin alpha IIbbeta 3 clustering in living cells. J Biol Chem 2003; 278: 15217-15224.
155. Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010; 9: 154-169.